Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Other Non-Current Assets: 2019-2025

Historic Other Non-Current Assets for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $805,000.

  • IDEAYA Biosciences' Other Non-Current Assets fell 11.64% to $805,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $805,000, marking a year-over-year decrease of 11.64%. This contributed to the annual value of $805,000 for FY2024, which is 6.34% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Other Non-Current Assets stood at $805,000 for Q3 2025, which was down 0.00% from $805,000 recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Other Non-Current Assets ranged from a high of $911,000 in Q2 2024 and a low of $106,000 during Q2 2022.
  • In the last 3 years, IDEAYA Biosciences' Other Non-Current Assets had a median value of $805,000 in 2025 and averaged $736,909.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first spiked by 646.23% in 2021, then slumped by 86.60% in 2022.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Other Non-Current Assets stood at $291,000 in 2021, then slumped by 63.57% to $106,000 in 2022, then surged by 614.15% to $757,000 in 2023, then grew by 6.34% to $805,000 in 2024, then declined by 11.64% to $805,000 in 2025.
  • Its Other Non-Current Assets was $805,000 in Q3 2025, compared to $805,000 in Q2 2025 and $805,000 in Q1 2025.